Your Source for BioScience Venture Capital Data
  • OnBioVC NEWS:

    - OnBioVC Announces Beta Launch of Service
    - OnBioVC INDEX(TM) Updated thru JUN 2010
    - OnBioVC 2Q10 Trend Analysis, now available
    - OnBioVC 3Q10 Trend Analysis, coming soon
  • SEARCH THE OnBioVC DATABASE:

  • investment bank middle market venture capital

Poxel (France) a clinical-stage small molecule company focused on Type-2 diabetes and metabolic disease, closed a $20.3M Series A financing. Participants include Edmond de Rothschild Investment Partners, InnoBio Ventures and Crédit Agricole Private Equity.

Nephera (Israel) a development-stage medical device company focused on kidney function in CHF patients, closed a $2.8M Series B financing. Participants include Aurum Ventures, Evergreen Venture Partners and Trendlines Group.

Pantech Biosolutions (Liechtenstein) a clinical-stage device company focused on a laser-based transdermal delivery system for large-molecular weight drugs, closed a $19M Series B financing. Participants include StemCell Holding and Gamma Capital Partners.

Curexo Technology (Korea) a commercial-stage medical device company focused on robotic surgical systems for joint replacement, closed a $13.2M Series C financing. Participants were not identified.

Green Biologics (United Kingdom) a development-stage biotechnology fermentation company focused on bio-butanol for biochemicals and biofuels, closed a $6.1M Series B financing. Participants include Capricorn Venture Partners, Morningside Ventures, Carbon Trust Investment Limited and Oxford Capital Partners.

Zymeworks (Canada) a development-stage bioinformatics company focused on in silico optimization of protein-based therapeutics, closed a $3.2M Series B financing. Participants include CTI Life Sciences Fund.

NanoPowers (Switzerland) a development-stage medical device company focused on urinary incontinence, closed a $4.5M Series A financing. Participants include Novartis Venture Funds, Initiative Capital Romandie and Gran Plasa.

Reinnervate (United Kingdom) a development-stage company focused on in vitro cell culture technologies, closed a $2M Series A financing. Participants include NorthStar Equity Investors.

Noxxon Pharma (Germany) a clinical-stage biopharmaceutical company focused on the development of aptamers for the treatment of inflammation and hematological indications closed a $40M Series D financing. Participants include NGN Capital, TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, Seventure Partners, VC Fonds Technologie Berlin, Dow Venture Capital, Fcp Medical BioHealth-Trends, IBG Beteiligungsgesellschaft Sachsen-Anhalt [...]

EarlySense (Israel) a development-stage medical device company focused on acute care patient supervision, closed a $13M Series C financing. Participants include Pitango Venture Capital, Etgar Challenge Fund, Proseed Ventures, Docor International Management, Noaber and Bridge Investment.

« Previous Entries  

to top of page...